Unknown

Dataset Information

0

Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer.


ABSTRACT:

Introduction

The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy.

Methods

Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local control.

Results

Between 01/2001 and 07/2022, 168 patients contributed demographic, tumor, pretherapy hemoglobin, and outcome data with a median follow-up of 31 months. Progression-free survival at three years was 73% (95% confidence interval: 58%-84%), 71% (95% confidence interval: 56%-82%), and 62% (95% confidence interval: 44%-75%) for the Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL groups, respectfully (P < 0.001). In addition, pretherapy hemoglobin levels were significant with treatment outcome when included in a multivariate analysis of prognostic variables.

Discussion

In conclusion, the difference in pretherapy hemoglobin level was prognostic of progression-free survival.

SUBMITTER: Kunos CA 

PROVIDER: S-EPMC10358846 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

altmetric image

Publications

Hemoglobin level associates with survival in women from Appalachian Kentucky with uterine cervix cancer.

Kunos Charles A CA   Fabian Denise D   Fredericks Tricia T   Baldwin Lauren L   Dietrich Charles C   Miller Rachel W RW   Ueland Frederick R FR  

Frontiers in oncology 20230706


<h4>Introduction</h4>The purpose of this retrospective study was to determine the relationship between pretherapy hemoglobin levels and progression-free survival among women with uterine cervix cancer undergoing concurrent weekly cisplatin and radiotherapy followed by brachytherapy.<h4>Methods</h4>Patients with advanced-stage II-IVA uterine cervix cancer were grouped by hemoglobin level (Hgb ≥ 12.0, 11.9-10.0, or < 10.0 g/dL). Endpoints were progression-free survival, overall survival, and local  ...[more]

Similar Datasets

| S-EPMC9902924 | biostudies-literature
| S-EPMC8495887 | biostudies-literature
| S-EPMC2510814 | biostudies-literature
| S-EPMC7941435 | biostudies-literature
| S-EPMC8830599 | biostudies-literature
| S-EPMC9905715 | biostudies-literature
| S-EPMC6189431 | biostudies-literature
| S-EPMC10470616 | biostudies-literature
| S-EPMC6363884 | biostudies-literature
| S-EPMC6392268 | biostudies-literature